摘要
目的探讨恶性血液病(MHD)患者血清血管内皮生长因子(VEGF)水平及其对疗效和预后的意义。方法采用双抗体夹心(ELISA)法检测76例初诊和复发难治性MHD患者以及24例初诊患者化疗后血清VEGF水平,并以18例健康体检者血清VEGF水平为对照。结果初诊和复发难治MHD患者血清VEGF分别为(210.17±97.54)ng/L和(251.71±141.34)ng/L,均高于对照组(98.13±45.36)ng/L和治疗有效组(120.48±77.36)ng/L(P<0.01);VEGF低于初诊平均值(207.35±119.43)ng/L的15例初诊患者化疗均有效,其余9例初诊患者VEGF水平高于平均值(207.35±119.43)ng/L的有效率为44%。结论检测MHD患者VEGF水平可作为疗效和预后判断指标。
[Objective] To explore serum vascular endothelial growth factor （VEGF） levels and Their prognostic significance with malignant hematologic diseases （MHD） patients. [Methods] Serum VEGF in 76 newly diagnosed and relapsed refractory MHD patients and part of them in newly diagnosed after chemiotherapy were determined by enzyme linked immuno sorbent assay （ELISA）. [Results] Serum VEGF levels in newly diagnosed and relapsed refractory MHD patients were （210.17±97.54） ng/L and （251.75±141.34） ng/L, obviously higher than control group （98.13±45.36） ng/L and effevtive group （120.48±77.36） ng/L （P 〈0.01）. 15 patients in newly diagnosed with VEGF below （207.35±119.43） ng/L were all effective, but the effect rate was 44% in the other 9 patients in newly diagnosed with VEGF above （207.35±119.43） ng/L. [Conclusion] The serum levels have prognostic significance in patients with MHD.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第9期1381-1383,共3页
China Journal of Modern Medicine
关键词
血管内皮生长因子
恶性血液病
vascular endothelial growth factor
Hematologic disease
malignant
